Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • January 16, 2025

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. PMID: 39817087; PMCID: PMC11734025.

Tags: amyloidosis, Cardiology/Epi, Outcomes, Publications, SGLT2 inhibitors, transthyretin amyloid cardiomyopathy

Toward Non-Invasive MR-Based Target Delineation for Ventricular Tachycardia Stereotactic Radiotherapy: Development of a 3D Wideband LGE MRI Technique

Dong H, Shih SF, Han F, Chin RK, Hayase JH, Bradfield JS, Bedayat A, Finn JP, Cao M, Zhong X. Toward Non-Invasive MR-Based Target Delineation[...]

Incremental Prognostic Value of Subendocardial Myocardial Flow Reserve in Patients With Normal Perfusion

Lopez DM, Brown JM, Divakaran S, Huck DM, Weber BN, Hainer J, Carre S, Lemley M, Ramirez G, Shanbhag A, Kavanagh P, Liang JX, Blankstein[...]

Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery disease

Kumar A, Van C, Shahrvini T, Srikanthan P, Horwich TB. Body composition changes during cardiac rehabilitation and long-term cardiovascular outcomes in patients with coronary artery[...]